UMONS ; FabLab Mons ; Fab-C Charleroi Métropole ; FabLab Wapi
" Visors for face masks produced at FabLab Mons. In collaboration with Fab-C Charleroi Métropole and FabLab Wapi, FabLab Mons is currently producing visors for nursing staff. These visors extend the life of the masks by preventing splash contamination. This has been made possible with the financial support of the FRMH and the donation of transparent sheets from multiple organisations, which has enabled the FabLab to distribute several thousand visors (23,000+ distributed to date) to medical doctors, nurses, pharmacists, physiotherapists, nursing home staff, opticians and audiologists. "
Contact: FabLab Mons https://fablabmons.be This email address is being protected from spambots. You need JavaScript enabled to view it.

AMB Ecosteryl
" AMB Ecosteryl (Mons), specialized in the treatment and sterilization of medical waste, has adapted its technology to develop a machine that decontaminates these masks (and therefore reuse them afterwards). This machine, named "M-steryl", allows, thanks to dry heat, to decontaminate 1.400 masks per day. This machine can easily be installed in hospitals, allowing staff to decontaminate their equipment individually. It requires only a power outlet and is easy to use. Each mask can be decontaminated three times, allowing for greater autonomy in terms of supply and lower costs. "
Contact: http://ecosteryl.com

Univercells
" The current COVID19 pandemic has imposed in a few months a global burden on humanity. A vaccine is urgently needed to protect people, communities, healthcare systems, and economies. In this context, Univercells joined forces with Reithera and Leukocare to develop and manufacture a novel adenovirus-based vaccine against COVID19. This vaccine candidate is expected to enter in clinical trials during summer 2020 and production to start soon after. Capitalizing on the bioproduction technologies of its newly created subsidiary Univercells Technologies, Univercells will produce at large-scale the vaccine candidate in Jumet. This site with 15,000 m² GMP capabilities offers the capacity to be ready for rapid response programs. Approximately 6 million doses are expected to be available in early 2021. The intention with these doses will be to vaccinate the most exposed people such as medical and healthcare professionals and highly vulnerable individuals. "
Publication References...

Read more: Hugues Bultot, CEO

Equaly sa
" Novel methods to prevent and treat Covid-19 viral infection by inhibiting virus entry "
Funding: not disclosed 

Equaly sa
" A novel strategy to prevent virus entry through the ACE2R A novel strategy for preventive vaccination to Covid-19 Monoclonal antibodies targeting the ACE2R are used to block virus entry. Vaccines are prepared eliciting a Th1response together with cytotoxic T cells. "
Funding: private
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Aesculape CRO Belgium BV
" Treatment of COVID 19 complications with antibodies "
Funding: partly public partly private
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it. 0492 735931

EXO Biologics
" EXO Biologics plans to extend its research and development program towards the COVID-19 crisis by using its unique and disruptive technology based on Extracellular Vesicles. These nanometer size particles are gaining momentum in the scientific community as potential alternatives to stem cell and biologic drugs therapies in the fields of immunology, neurology, oncology, cardiology, gastroenterology among others. EXO Biologics has 12 years of experience in cell-based regenerative medicine and 8 years of experience in Extracellular Vesicles. Our advancements in research will play an important role for our company mission to provide affordable and accessible therapies to patients with unmet medical needs. "
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

DELTRIAN
" Deltrian has developed four complete production lines for surgical masks (production and packaging) which will be operational in Fleurus from the end of May 2020. Deltrian will produce 160 surgical masks per minute following a work divided into two breaks. That is a total of 60 million masks per year. A shift to three breaks could even increase production to 90 million masks per year. In response to a request from the federal government and together with the company Sioen (Ardooie, West Flanders), Deltrian will also have the task of producing 20 million filters that will be used to improve the quality of cloth masks that will be compulsory to wear on public transport from 4 May 2020. This is part of a desire to repatriate certain know-how to Wallonia and is an integral part of the Region's reindustrialisation strategy. "
Contact: http://www.deltrian.com/

3D-Side S.A.
" "- 3D printing of swabs in SLS - 3D printing of valves - 3D printing of connectors for respiratory systems - Advice on guidelines on the manufacturing and post processing of such devices." "
Contact: Khanh TRAN DUY This email address is being protected from spambots. You need JavaScript enabled to view it.

Covartim
"In the global effort to help the healthcare professionals in the fight against the Covid pandemic, we are providing documents to help manufacturers that are not familiar with medical devices to properly document their work to help them in their product development and achieving compliance. These templates are derived from our technical file documentation and include some reference to guidances (mostly applicable in Belgium) for devices and accessories to answer to hospital products shortage."
Contact : Covartim www.covartim.be This email address is being protected from spambots. You need JavaScript enabled to view it.

UCLouvain, Datatext
“The project aims at measuring the impact of the Covid-19 crisis on the French-speaking Belgium population through the analysis of discourses on social media. In particular, we work on an open corpus of (today) 4.000 tweets from politicians, 30.000 from the media and 100.000 from the population. All messages include a Covid-19 related expression. We focus on three main research topics: (1) the diachronic evolution of discourses, from the emergence of the disease in China to reopening plans, through lockdown measures; (2) the impact of political discourse on the acceptance of measures by citizens and (3) the role of the language used by the media in measures’ acceptance and anxiety of the population.”
Funding: Seeking funding 
Contact: Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.  Website: https://uclouvain.be/instituts-recherche/ilc/miil/reseaux-sociaux.html 

ULiège + Mesylab SRL
" How to securely return to normalcy at work? All countries consider to lift the lockdown, but few have executed it. There are no "best practices". Questions abound: What are the risks? What are the most effective measures? Will communities follow? What are the consequences for our individual lives? Who decides how to proceed? AIMS OF THE PROJECT GIGA aims at defining the best possible approach to opening up again by involving its members. Your opinion matters. GIGA has sought assistance in conducting this real time experiment from political scientists, philosophers, lawyers and medical doctors. "
Contact: This project is supported by the GIGA office and is coordinated by the ad hoc Advisory Committee made up of expert political scientists in participation (Dr. F. Thoreau, Dr. C. Parotte, Dr. P. Delvenne, Dr. C. Fallon), a political and ethicist philosopher (Dr. F. Caeymaex) and doctors (Dr. Y. Beguin, Dr. G. Darcis).

BECARV SA
" BECARV supplies and install solution and equipement for labs, such as modular biosafety cabinets, air purifier for containment of a room, filter units, etc "
Contact: www.becarv.be Michaël Jeanty This email address is being protected from spambots. You need JavaScript enabled to view it.

Coris BioConcept
" Early February we started the development of a rapid antigen detection assay for SARS-CoV-2. The COVID-19 Ag Respi-Strip Assay was validated in three University hospital laboratories and registered (CE mark) by end of March. The test is designed as a first line triage assay to be used for rapid (15 minutes) detection of SARS-CoV-2 on symptomatic patients. We are currently developing a serological assay that targets the immune response against several antigens of the virus. "
Publication References: https://jcm.asm.org/content/jcm/early/2020/05/11/JCM.00977-20.full.pdf https://www.frontiersin.org/articles/10.3389/fmed.2020.00225/full?utm_campaign=ba-cov-sci-fmed-respi-strip&utm_medium=cvlp&utm_source=fweb
Contact: https://www.corisbio.com/Products/Human-Field/Covid-19.php product-sales: This email address is being protected from spambots. You need JavaScript enabled to view it. science-R&D: This email address is being protected from spambots. You need JavaScript enabled to view it.

Aseptic Technologies SA
" Table-top equipment for FFP2 mask decontamination by means of UV-C, developed jointly by Lasea s.a. and Aseptic Technologies s.a. Allows re-use of FFP2 masks up to 5 times (under validation process) "
Contact: Patrick Baleriaux CEO Aseptic Technologies s.a This email address is being protected from spambots. You need JavaScript enabled to view it.